Consistent with the Taiwanese data, the TCGA dataset also revealed that methylation at the five specific CpG sites of SRCIN1 did not significantly differ among lung cancer, colon cancer, esophageal cancer, uterine cancer, liver cancer, pancreatic cancer and gastric cancer patients (Figure 3B and Supplemental Figure S3). Here, SRCIN1 is linked to pancreatic neoplasm.